NUVB - Nuvation Bio sheds ~14% as FDA imposes partial hold on cancer trial

Nuvation Bio (NYSE:NUVB) dropped ~14% in the pre-market Monday after the clinical-stage biopharmaceutical company announced that the FDA imposed a partial clinical hold on an early-stage trial for its lead candidate NUV-422 in cancer. The Phase 1 dose escalation study was designed to trial the small molecule inhibitor in solid tumors, including high grade glioma, HR+/HER2- advanced breast cancer and metastatic castration resistant prostate cancer. The partial clinical hold followed the emergency of an eye inflammation called uveitis after the company started exploring higher doses to find a maximum tolerated dose, Nuvation (NUVB) said. The management intends to update on the NUV-422 program after incorporating the FDA feedback to an internal risk-benefit analysis it plans to start.

For further details see:

Nuvation Bio sheds ~14% as FDA imposes partial hold on cancer trial